Wegovy (semaglutide) Wegovy is a GLP-1 agonist medication that is approved to: Aid in weight loss for adults and children over 12 years old who have obesity, or in adults who have overweight and have a weight-related health condition (such as high blood pressure, type 2 diabetes , or high cholesterol) Reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults who have cardiovascular disease and have obesity or overweight Wegovy comes in a single-use pen that you inject once per week, either with or without food
Retatrutide is a triple-hormone receptor agonist from Eli Lilly that produced 2428% average weight loss in Phase 2 trials, significantly exceeding the 1215% typical of semaglutide and the 1522% of tirzepatide
By Graeme Walker Excellent service
The JPMLs order came after at least 18 GLP1 lawsuits have been filed in various different federal district courts nationwide, each raising nearly identical allegations that drug makers rushed to get their GLP-1 drugs onto the market amid a rapid increase in popularity without first adequately researching the full safety profile and side effects
Semaglutide Injection (Wegovy) for weight loss is now under review, following the authorization application submitted in June 2023
Understanding each stage can help patients and providers prepare complete records and respond without unnecessary delay
